放疗联合尼妥珠单抗注射液及热疗对比同步放化疗治疗老年局部中晚期宫颈癌的临床观察

doi:10.3969/j.issn.1006-6233.2026.01.025

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1238 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 评估尼放疗联合尼妥珠单抗注射液及热疗治疗老年局部中晚期宫颈癌的有效性及安全性。方法: 回顾性纳入2021年1月至2022年12月承德医学院附属医院肿瘤科收治的62例老年性局部中晚期宫颈癌患者,观察组31例,给予尼妥珠单抗注射液联合放疗及热疗,对照组31例,给予同步放化疗。评价治疗近期及远期疗效,以及不良反应。结果: 观察组23例患者达到CR,6例患者达PR,1例患者为SD,1例PD,客观缓解率96.77%;对照组21例患者达到CR,5例患者达PR,2例患者为SD,3例PD,客观缓解率90.32%,两组比较差异无统计学意义。远期疗效方面,观察组患者 2年 PFS为 87.10% ,2年 OS为96.77%; 对照组患者 2年 PFS为 80.65%, 2年 OS为 90.32%,两组比较差异无统计学意义(P>0.05)。两组免疫功能比较,CD4⁺细胞以及CD4⁺/CD8⁺均在治疗后有所升高,且观察组较对照组升高明显,两组比较差异有统计学意义(P<0.05)。两组主要不良反应为中性粒细胞减少、腹泻、尿路刺激症状、贫血和皮肤黏膜炎,观察组以1~2级不良反应为主,未发生3级以上不良反应,对照组腹泻、尿路刺激症状方面有3级不良反应发生,两组不良反应发生率比较在腹泻和尿路刺激症状方面观察组发生率低于对照组,差异有统计学意义(P<0.05)。结论: 放疗联合尼妥珠单抗注射液及热疗治疗老年局部晚期宫颈癌治疗疗效与同步放化疗相当,但不良反应明显降低。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：宫颈癌, 放射治疗, 热疗, 尼妥珠单抗

Abstract：Objective: To investigate the efficacy and safety of Nimotuzumab combined with radiotherapy and hyperthermia in the treatment of elderly patients with locally advanced cervical cancer. Methods: The retrospective study included 62 elderly patients with locally advanced cervical cancer treated in the Oncology Department of the Affiliated Hospital of Chengde Medical University from January 2021 to December 2022. The observation group (31 cases) received Nimotuzumab injection combined with radiotherapy and hyperthermia, while the control group (31 cases) received concurrent chemoradiotherapy. Short-term and long-term efficacy, as well as adverse reactions, were evaluated. Results: In the observation group, 23 patients achieved complete response (CR), 6 achieved partial response (PR), 1 had stable disease (SD), and 1 had progressive disease (PD), yielding an objective response rate (ORR) of 96.77%. In the control group, 21 achieved CR, 5 PR, 2 SD, and 3 PD, with an ORR of 90.32%. There was no statistically significant difference in ORR between the two groups. For long-term outcomes, the 2-year progression-free survival (PFS) and overall survival (OS) rates in the observation group were 87.10% and 96.77%, respectively, compared to 80.65% and 90.32% in the control group, with no significant differences. Post-treatment immune function analysis showed that CD4⁺ cell counts and the CD4⁺/CD8⁺ ratio increased in both groups, with a more pronounced elevation in the observation group (P<0.05). The main adverse reactions included neutropenia, diarrhea, urinary tract irritation symptoms, anemia, and mucositis. The observation group primarily experienced Grade 1 to 2 adverse reactions, with no Grade 3 or higher adverse reactions occurring. In contrast, the control group experienced grade 3 diarrhea and urinary tract irritation symptoms. The incidence of diarrhea and urinary tract irritation was significantly lower in the observation group (P<0.05). Conclusion: Nimotuzumab combined with radiotherapy and hyperthermia demonstrates comparable efficacy to concurrent chemoradiotherapy in treating elderly patients with locally advanced cervical cancer but with significantly reduced adverse reactions.

Key words： Cervical cancer Radiotherapy Hyperthermia Nimotuzumab

基金资助:河北省承德市科技计划项目,(编号:202303A046)

通讯作者: 白璐

引用本文:

杨纪元, 石方玉, 董辉, 李青山, 白璐. 放疗联合尼妥珠单抗注射液及热疗对比同步放化疗治疗老年局部中晚期宫颈癌的临床观察[J]. 河北医学, 2026, 32(1): 157-163.
YANG Jiyuan, et al. Comparison of Nimotuzumab Combined with Radiotherapy and Hyperthermia versus Concurrent Chemoradiotherapy in the Treatment of Elderly Patients with Locally Advanced Cervical Cancer. HeBei Med, 2026, 32(1): 157-163.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2026.01.025 或 http://www.hbyxzzs.cn/CN/Y2026/V32/I1/157

[1] Qi J,Li M,WANG L,et al.National and subnational trends in cancer burden in China,2005-20:an analysis of national mortality surveillance data[J].Lancet Public Health,2023,8(12):943-955.
[2] Darlin L,Borgfeldt C,Widen E,et al.Elderly women above screening age diagnosed with cervical cancer have a worse prognosis[J].Anticancer Res,2014,34(9):5147- 5151.
[3] 肖鑫,盛晓安,施险峰,董娟娟,许娟,汪超.热疗联合同步放化疗对中晚期宫颈癌的临床疗效及血清热休克蛋白90α表达的影响[J].中华全科医学,2022,20(7):1109-1112.
[4] Cao Y,Deng L,Lian S,et al.Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer[J].JBUON,2019,24(5):2013-2019.
[5] 卓延红,王尤佳,陈丽民等。尼妥珠单抗同步调强放射治疗对老年局部晚期子宫颈癌的安全性和有效性研究[J]。中华放射医学与防护杂志,2022,42(12):928-933.
[6] 何玥,吴玉梅,王建东,等.老年女性子宫颈病变筛查及异常管理中国专家共识(2023年版)[J].中国实用妇科与产科杂志,2023,39(5):531-536.
[7] Ferrall L,Lin KY,Roden RBS,et al.Cervical cancer immunotherapy:facts and hopes[J].Clin Cancer Res,2021,27(18):4953-4973.
[8] Rose PG,Bundy BN,Watkins EB,et al.Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin,cisplatin-based combination chemotherapy,or hydroxyurea during pelvic irradiation for locally advanced cervical cancer:a gynecologic oncology group study[J].Journal of Clinical Oncology,2007,25(19):2804-2810.
[9] 陈杰,曹元杰,朱莉,等.尼妥珠单抗联合同步放化疗治疗局部晚期宫颈癌的临床观察[J].中华医学杂志,2021,101(8):597-601.
[10] Wang Junjie,Jiang Ping.;Wei Lichun et al.759P Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma:a randomized,controlled,open-label,multicenter study[J].Annals of Oncology,2023,34(1):518-519.
[11] Jacoba Van der Zee MD,Gonzalez Gonzalez,van Rhoon GC,et al.Comparison of radiotherapy plus hyperthermia in locally advanced pelvic Tumour:a prospective,randomised,multicentre trial[J].The Lancet,2000,355(9210):1119-1125.
[12] Kanwal Ahmed,Syed Faisal Zaidi,Mati-Ur-Rehman.Hyperthermia and protein homeostasis:cytoprotection and cell death[J].Journal of Thermal Biology,2020,9(91):102615.
[13] Wang W,Hou X,Yan J,et al.Outcome and toxicity of radical radiotherapy or concurrent chemoradiotherapy for elderly cervical cancer women[J].BMC Cancer,2017,17(1):510.
[14] 张志臣, 李悦,黄磊,等.热放化疗治疗局部晚期宫颈癌的疗效及安全性分析[J].癌症进展,2021,19(1):81-84.